Additional biomarkers may help colorectal cancer testing

10/19/2009 | Medscape (free registration)

Testing patients with metastatic colorectal cancer for their KRAS status plus three other biomarkers could nearly double the identification rate of people who likely will not respond to anti-epidermal growth-factor receptor targeted therapy, Italian researchers reported. The additional biomarkers, however, need further testing and are not ready for clinical use, one expert said.

View Full Article in:

Medscape (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Medical Device Reimbursement Specialist - Regional
Alcon
Fort Worth , TX
Assistant General Counsel/Senior Corporate Counsel - Healthcare Law Group
Genentech
94080, CA
Clinical Trials Agreements Specialist (209955)
The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.
Rockville, MD
SAFETY, HEALTH, and ENVIRONMENTAL (SHE) REGIONAL SPECIALIST
Matheson Tri-Gas, Inc.
Newark, CA
MANAGER MEDICAL GAS COMPLIANCE AND SAFETY
Matheson Tri-Gas, Inc.
Houston, TX